What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
iTechGuides is reader-supported. When you buy through links on our site, we may earn an affiliate commission. As an Amazon Associate I earn from qualifying purchases. Learn more
The likely drug behind this question is daraxonrasib (RMC-6236), a RAS(ON) inhibitor. The title does not name a drug, so this article focuses on daraxonrasib while distinguishing what is known about it from broader research on KRAS inhibitors. The central clue is that pancreatic tumors are made up of varied cancer cells: treatment may select for cells with genetic changes or cell states that make them less dependent on the pathway the drug blocks.
That is a developing explanation, not one proven mechanism for every patient. Much of the evidence about changing cell states comes from laboratory and mouse studies, while a 2026 daraxonrasib study examined tumor-DNA samples from patients whose cancers had acquired resistance.
What is daraxonrasib, and what does “stops working” mean?
Daraxonrasib targets RAS signaling, a pathway that helps cancer cells grow and survive. In September 2026, the National Cancer Institute reported that the U.S. Food and Drug Administration had approved it for advanced pancreatic cancer that had already been treated. That approval does not mean it is approved for every pancreatic cancer stage or that it cures the disease. The NCI says more than 90% of pancreatic cancers have KRAS mutations, which is why altered KRAS is a major focus of targeted-therapy research. National Cancer Institute: Advances in Pancreatic Cancer Research
Recommended Free Tools
When a drug “stops working,” it means the cancer is growing or progressing despite treatment. A tumor can contain cell populations with different characteristics, and treatment can change which populations remain. Resistance does not necessarily mean every cancer cell acquired the same mutation—or that one test will reveal a single cause.
#1 Best Overall
Pancreatic cancer includes more than one cancer type. Most of the resistance findings discussed below concern pancreatic ductal adenocarcinoma (PDAC), and they should not be assumed to apply identically to every pancreatic cancer or every patient taking daraxonrasib.
How can cancer cells escape a KRAS-pathway inhibitor?
Genetic changes can create multiple routes around treatment
Under treatment pressure, some cancer cells may acquire or select for genetic alterations that help them survive despite inhibition of RAS signaling. These changes can vary from tumor to tumor. As Andrew Aguirre, M.D., Ph.D., of Dana-Farber Cancer Institute, told the NCI, “We’ve seen several different genetic alterations emerge that cause tumors to become resistant” to KRAS inhibitors. The observation points to diverse escape routes rather than one universal resistance mutation. NCI: Can Chemo Help KRAS Inhibitors Work Better Against Pancreatic Cancer?
Rank #2
Cells may shift into a less KRAS-dependent state
Cancer cells can also change their gene-expression programs—the patterns of genes they use—without all acquiring the same new DNA mutation. In research summarized by the NCI, KRAS inhibition was followed by a larger share of cells in a “classical” state that appeared less reliant on KRAS for survival. This gives a tumor another possible way to persist: some cells may become less vulnerable to blocking the pathway rather than finding the same genetic workaround.
The cell-state findings include laboratory and mouse work. They offer a plausible explanation for resistance, but do not establish that this shift is what caused daraxonrasib resistance in every patient. Christine Alewine, M.D., Ph.D., of the NCI’s Center for Cancer Research, described cell-state flexibility as a potentially important driver in the studies available at the time; it remains an expert interpretation of developing evidence, not a settled rule for individual tumors. NCI: Can Chemo Help KRAS Inhibitors Work Better Against Pancreatic Cancer?
What can tumor DNA tests reveal about resistance?
A 2026 Nature Medicine study examined paired circulating tumor DNA (ctDNA) samples collected before treatment and at the end of treatment from 44 phase 1/2 trial patients whose tumors had acquired resistance to daraxonrasib. The researchers used targeted sequencing that covered more than 800 genes. This human-sample analysis can help identify genetic changes associated with resistance, but its cohort and design do not establish how often each mechanism occurs across all treated patients or which one is dominant. Nature Medicine: Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer
A blood test that detects ctDNA can reveal some tumor genetic changes, but a result without an identified resistance alteration does not show that the cancer has no resistance mechanism. A 2024 review reported that no putative genetic resistance mechanism was identified in 54% of PDAC cases in one cited ctDNA-based analysis. The authors discussed incomplete detection and non-genetic mechanisms as possible explanations; the figure applies to that analysis and its methods, not to all patients receiving daraxonrasib. Cancer Discovery: Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
How do the treatment approaches and evidence compare?
| Approach or clue | How it may matter | Evidence and limit |
|---|---|---|
| Direct RAS/KRAS-pathway inhibition | Blocks a growth-and-survival signal that is altered in many pancreatic cancers. | Daraxonrasib’s 2026 patient-sample study investigated acquired resistance; it does not show one mechanism explains every case. |
| Chemotherapy | Gemcitabine and nab-paclitaxel attack cancer cells through broader cytotoxic effects rather than only blocking RAS signaling. | In one mouse model summarized by the NCI, adding these drugs to experimental KRAS inhibitor MRTX1133 produced an average tumor-size reduction about 60% greater than KRAS inhibition alone. This is an animal result, not an estimate of patient response. |
| Single-agent treatment versus combinations | A combination could affect cells that respond differently to pathway blockade. | The NCI summarized two mouse studies in which MRTX1133 plus gemcitabine and nab-paclitaxel reduced tumor growth more than either approach alone. This does not establish an optimal human regimen or prove that a combination prevents resistance to daraxonrasib. |
| Genetic resistance versus cell-state adaptation | Genetic alterations may be detectable in tumor DNA; shifts in gene-expression state may not appear as a clear resistance mutation. | Clinical samples support investigation of genetic changes; state-shift evidence described by the NCI includes laboratory and animal work. Neither category supplies a validated test that predicts an individual patient’s outcome. |
The NCI describes adding to standard chemotherapy, rather than eliminating it, as a possible direction for improving KRAS-inhibitor treatment. That is a research rationale, not a treatment recommendation or proof that chemotherapy combinations will overcome resistance in people. NCI: Can Chemo Help KRAS Inhibitors Work Better Against Pancreatic Cancer?
Windows Errors? Fix Them Before They Spread
Repair common Windows errors and clear accumulated junk for a smoother, more stable PC - no reinstall needed.Free scan · no reinstallCrashes, No Sound, or Screen Glitches?
Random freezes, missing sound and display glitches usually trace back to one bad driver. Find and replace yours safely.Free scan · under a minuteWhat is not yet known, and what should patients do?
Current evidence does not establish which resistance mechanism dominates in the full daraxonrasib patient cohort, what proportion of treated patients develops each mechanism, a validated test that predicts when resistance will occur, or a proven treatment sequence that prevents it. Nor do mouse combination results establish which regimen, if any, will help a particular patient.
The NCI recommends tumor biomarker testing for people with advanced or metastatic pancreatic cancer, because results can help inform treatment options. If scans or symptoms suggest a treatment is no longer controlling the cancer, the oncology team can interpret the clinical picture and any available tumor or blood-test results. Decisions about changing treatment belong with that team; mechanistic research alone cannot determine the right next step for an individual.
For the broader clinical context and biomarker information, see the NCI’s pancreatic cancer research overview.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
Free tools Windows power users keep installed
One-click scans. No signup required.
